Compounds > a 75925
Page last updated: 2024-12-06

a 75925

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A 75925: has HIV antiviral & HIV type 1 protease inhibitory activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72290
CHEMBL ID289846
SCHEMBL ID6446780
MeSH IDM0199091

Synonyms (22)

Synonym
142861-15-2
2,5-diamino-n,n'-bis(n-benzyloxycarbonylvalyl)-1,6-diphenyl-3(r),4(r)-hexanediol
l-iditol, 1,2,5,6-tetradeoxy-2,5-bis[[(2s)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-1,6-diphenyl-
bzocvalphe[dichoh(rr)]phevalbzoc
129467-48-7
benzyl n-[(1s)-1-[[(1s,2r,3r,4s)-1-benzyl-4-[[(2s)-2-(benzyloxycarbonylamino)-3-methyl-butanoyl]amino]-2,3-dihydroxy-5-phenyl-pentyl]carbamoyl]-2-methyl-propyl]carbamate
a 75925
q8024
a-75925
CHEMBL289846 ,
benzyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
bdbm50064200
benzyl (2s,2''s)-1,1''-((2s,3r,4r,5s)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)bis(azanediyl)bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
{(s)-1-[(1s,2r,3r,4s)-1-benzyl-4-((s)-2-benzyloxycarbonylamino-3-methyl-butyrylamino)-2,3-dihydroxy-5-phenyl-pentylcarbamoyl]-2-methyl-propyl}-carbamic acid benzyl ester
bzocvalphe(dichoh(rr))phevalbzoc
l-iditol, 1,2,5,6-tetradeoxy-2,5-bis(((2s)-3-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)butyl)amino)-1,6-diphenyl-
(2(s),5(s))-1,2,5,6-tetradeoxy-2,5-bis((3-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)butyl)amino)-1,6-diphenyl-l-iditol
l-iditol, 1,2,5,6-tetradeoxy-2,5-bis((3-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)butyl)amino)-1,6-diphenyl-, (2(s),5(s))-
SCHEMBL6446780
dibenzyl ((2s,2's)-(((2s,3r,4r,5s)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)bis(azanediyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate
bdbm586099
AKOS040747671

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Additional pharmacokinetic studies in dogs and monkeys revealed the potential utility of A-77003 as an intravenous anti-HIV agent."( Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
Bryant, P; Codacovi, L; Kempf, DJ; Knigge, MF; Kohlbrenner, WE; Marsh, KC; Norbeck, DW; Paul, DA; Vasavanonda, S; Wang, XC, 1991)		0.28

Bioavailability

ExcerptReferenceRelevance
" After administration of the inhibitors to rats, short half-lives and, with two notable exceptions, moderate oral bioavailability were observed."( Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
Bryant, P; Codacovi, L; Kempf, DJ; Knigge, MF; Kohlbrenner, WE; Marsh, KC; Norbeck, DW; Paul, DA; Vasavanonda, S; Wang, XC, 1991)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1IC50 (µMol)0.00020.00010.22487.3200AID161507; AID162040
Protease Human immunodeficiency virus 1IC50 (µMol)0.00200.00000.81769.8500AID449367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID449367Inhibition of HIV1 protease expressed in Escherichia coli K12 assessed as inhibition of enzyme activity2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
AID161507Inhibitory activity was measured against wild-type HIV-1 protease1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
AID1318772Inhibition of recombinant HIV-1 protease using Lys-Ala-Arg-Val-Tyr-Phe(NO2)-Glu-AlaNle-NH2 as substrate2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
AID162040Inhibition of HIV-1 protease1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
AID1799479Inhibition Assay from Article 10.1016/S1074-5521(02)00184-9: \\A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors.\\2002Chemistry & biology, Aug, Volume: 9, Issue:8
A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (57.14)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.19 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
betaxolol
[no description available]		2.1310propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		2.1310aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		1.9710L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9910azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
sezolamide
sezolamide: decreases intraocular pressure, topically in vivo; inhibits carbonic anhydrase; RN given refers to parent cpd without isomeric designation		3.0810
abbott 77003
Abbott 77003: a symmetry-based inhibitor of HIV-1 protease		3.0810
a 74704
A 74704: structure given in first source		3.4820
a 76889
A 76889: backbone structure gvien in first source		3.4920
a 76928
A 76928: a diol with C2-symmetry		3.5120
roflumilast
[no description available]		2.1310aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
ly335979
[no description available]		2.1310carbopolycyclic compound
montelukast
montelukast: a leukotriene D4 receptor antagonist		2.1310aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
pitavastatin
pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.		2.1310cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
dorzolamide
dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.		3.0810sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
nalmefene
nalmefene: RN given refers to 5-alpha isomer		2.1310morphinane alkaloid
verlukast
verlukast: LTD4 receptor antagonist		2.1310
volasertib
BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source		2.1310
e 7050
[no description available]		2.1310aromatic ether
cabozantinib
cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.		2.1310aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
gsk 1363089
GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source		2.1310aromatic ether
dcc-2701
DCC-2701: inhibits c-Met protein, TIE-2 protein, and vascular endothelial growth factor receptor		2.1310
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		02.4220
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.4220